🇺🇸

Index Intelligence

· daily

Nasdaq 100 Stocks SEC Filings — May 18, 2026

The 18 filings reveal a bifurcated landscape: while Genco Shipping & Trading and CoStar Group show strong operational turnarounds and proactive capital allocation, several biotech and cash-burning companies (Estrella Immunopharma, Madison Technologies) face liquidity pressures. Period-over-period comparisons highlight Genco's net income swing of +$21.2M YoY and CoStar's $1.5B buyback authorization, contrasting with Estrella's 28.5% G&A surge and Madison's zero revenue. Insider activity is limited but notable: Genco's CEO actively defends against a tender offer, while Acadia Healthcare faces a $105M adverse verdict. Forward-looking catalysts include MetaVia's ADA abstracts and ImmunityBio's BCG approval path. Sector themes center on capital discipline (shipping, real estate) versus speculative biotech spending, with a cautious tech hedge evidenced by Arkadios Wealth Advisors' large QQQ put positions.

5 high priority 13 medium 18 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 18, 2026

The May 18, 2026 batch of 50 S&P 500 Financials filings reveals a sector bifurcated between large-cap stability and small/mid-cap distress. The most significant event is the $2.5B all-cash acquisition of LiveRamp by Publicis Groupe at a 30% premium, signaling strong M&A appetite for data assets. However, this is overshadowed by severe distress signals: Bitcoin Depot has entered bankruptcy proceedings, and Gossamer Bio is executing a coercive debt-for-equity swap requiring 98% participation. Period-over-period trends show a mixed picture: LiveRamp's 9% YoY revenue growth and 107% net retention contrast sharply with iSpecimen's 85% revenue collapse and OLB Group's 29% decline. Insider activity is notably absent across most filings, but management actions—such as Wyndham's CEO disclosing a cancer diagnosis while reaffirming guidance—provide nuanced signals. Capital allocation trends are defensive: Coeur Mining has aggressively repurchased $69.7M of stock, while Presidio Property Trust is cutting debt and CEO pay. The overarching theme is capital preservation and strategic repositioning, with M&A and restructuring dominating the narrative over organic growth.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 18, 2026

The 50 filings for the S&P 500 Consumer Staples stream reveal a sector in transition, with significant capital allocation shifts, governance battles, and a few high-growth outliers. While the majority of filings are procedural (annual meeting results, proxy statements), several high-materiality events stand out. **Altria Group** faces a high-risk director departure, while **CoStar Group** is undertaking a major governance and capital allocation overhaul in response to activist pressure, including a $1.5B buyback. **CleanCore Solutions** presents a significant red flag with a material restatement and internal control weakness, contrasting with **Koil Energy Solutions** which reported record revenue and a return to profitability. **Claritev Corp** disclosed a DOJ antitrust probe, adding regulatory risk. The most actionable themes are the push for shareholder-friendly capital returns (CoStar, CCEP) and the severe financial reporting issues at CleanCore, which serve as a cautionary tale for micro-cap investors. Overall, the sector shows a mix of stable, cash-generating businesses returning capital and smaller players facing existential challenges.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 18, 2026

The 50 filings from the S&P 500 Industrials stream reveal a sector bifurcated between robust growth in niche areas (e.g., shipping, medical devices) and significant financial distress in others (e.g., Bitcoin Depot's Bitcoin Depot's bankruptcy, Banzai's dilution). Period-over-period data shows strong revenue growth at Bally's (+28.3% YoY) and Genco Shipping (swinging to a $9.3M profit from an $11.9M loss), but also highlights margin compression and cash burn at several firms. Insider activity is limited, but the heavy insider-related financing at Yale Transaction Finders and the departure of FedEx's CAO are notable. Capital allocation trends are mixed, with Bally's refinancing debt and Genco raising dividends, while others like Tofutti Brands and ABVC Biopharma face severe cash constraints. The most critical developments include Bitcoin Depot's bankruptcy, Bally's major project advancements, and the FedEx Freight spin-off, which together signal a 'survival of the fittest' dynamic in the industrials space.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 18, 2026

The three filings for the S&P 500 Energy stream on May 18, 2026, represent a very quiet session with no direct energy sector activity. The primary developments are procedural steps in XOMA Royalty Corp's merger with Ligand Pharmaceuticals, involving a holding company reorganization that does not alter economic terms. Chesapeake Wealth Management's 13F filing provides a snapshot of a diversified portfolio with no energy-specific concentration. No period-over-period comparisons, insider trading, forward-looking guidance, or capital allocation changes were present in any of the filings, limiting actionable insights. The absence of energy sector filings and the lack of enriched data trends (e.g., revenue growth, margin changes) indicate a lull in sector activity. Investors should monitor for upcoming earnings calls and regulatory decisions from major energy companies to identify future catalysts.

1 high priority 2 medium 3 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 18, 2026

The May 18, 2026 batch of 50 filings from the Dow 30 universe reveals a market bifurcated between aggressive capital deployment and operational strain. A dominant theme is the use of equity-linked financing and M&A to fund growth, with notable examples including LiveRamp's $2.5B all-cash acquisition by Publicis Groupe at a 30% premium, Bally's $4.0B Bronx development and $1.1B refinancing, and Soluna's $53M wind farm acquisition. However, this expansion is occurring against a backdrop of widening losses and cash burn for many companies, as seen in Soluna's net loss doubling to $17.9M and ABVC Biopharma's 79% loss increase with zero revenue. Insider activity is sparse but notable, with director resignations at Innoviva and significant shareholder dissent on pay at Nicolet Bankshares (32.7% against). Capital allocation is mixed: while some firms like Virgin Galactic are using stock to pay down debt, others like Babcock & Wilcox are raising $200M via dilutive offerings. The forward-looking calendar is rich with catalysts, including the July 6, 2026 Clough fund meetings and the May 19, 2026 NBT Bancorp annual meeting, but also carries risks from pending regulatory approvals (CFIUS on LiveRamp) and ongoing Nasdaq compliance issues (Faraday Future). Overall, the data suggests a market where strategic bets are being placed, but the financial health of the underlying companies requires close scrutiny of cash flow and margin trends.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 18, 2026

The 50 filings from the S&P 500 Consumer Discretionary sector reveal a sector in transition, marked by aggressive capital restructuring, significant insider activity, and a clear bifurcation between companies investing for growth and those facing operational headwinds. A dominant theme is the use of high-cost debt and equity-linked financing, with Wayfair issuing $400M in 7.125% notes and Faraday Future securing $70M in convertible notes, signaling elevated borrowing costs and potential dilution. Insider trading patterns are a key signal, with the CEO of Fermi Inc. ousted for cause and a proxy battle underway, while O'Reilly Automotive's board approved a $2M stock option for its executive chairman, indicating confidence. Period-over-period data shows mixed performance: Fatpipe Inc. grew revenue 17.9% YoY but saw operating cash flow turn negative, while Tofutti Brands saw sales decline 2.1% and losses widen. Capital allocation is a key differentiator, with InfuSystem announcing a $20M buyback and O'Reilly maintaining shareholder returns, contrasting with the dilutive financing at Flux Power and Profusa. The most critical development is the $1.5B MiRus investment by Boston Scientific, a bold bet on the TAVR market, while the ongoing proxy fight at Fermi Inc. and the short-term forbearance at FiscalNote highlight governance and liquidity risks. Overall, the sector shows a 'haves and have-nots' dynamic, where strong balance sheets are being used for strategic M&A and buybacks, while weaker players are forced into costly financing and face shareholder activism.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 18, 2026

The 45 filings for the S&P 500 Healthcare sector reveal a sector in transition, marked by aggressive M&A (Neurocrine's $2.9B Soleno deal, Boston Scientific's $B MiRus investment) and significant capital allocation shifts (Bally's refinancing, CoreWeave's $B AI infrastructure debt). Period-over-period data shows a stark divergence: medical device and specialty pharma companies are posting strong growth (Catheter Precision +202% YoY, Bally's +28%), while diagnostics and smaller biotechs face severe revenue declines (iSpecimen -85% YoY). Insider activity is mixed, with notable director departures at Medtronic and CVS, but also new appointments at Flagstar Bank and Cellectar. Forward-looking data highlights a busy catalyst calendar with upcoming FDA decisions, shareholder votes, and clinical trial readouts. Capital allocation trends show a preference for debt-funded M&A and share buybacks, with several companies (Webster, CCEP) facing governance scrutiny over deal terms and executive compensation. Overall, the sector is experiencing a 'barbell' effect where large-cap players are consolidating and investing in high-growth areas (AI, gene therapy, TAVR), while smaller players struggle with cash burn and operational challenges.

15 high priority 30 medium 45 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 14, 2026

Across 41 filings in the USA S&P 500 Technology stream, a dominant theme is robust revenue acceleration in select tech, space, and comms firms (e.g., Applied Materials +11% YoY to $7.91B, Intuitive Machines 3x YoY to $186.7M, GameSquare +95% YoY to $14.5M), contrasted by profitability volatility and cash burn pressures amid M&A (Iridium $366.7M Aireon deal, Intuitive $800M Lanteris). Period-over-period trends show 7/15 quarterly reporters posting YoY revenue growth averaging +55% (outliers: ImmuCell +28%, RideNow +6.4%), but 6/15 saw net losses widen or emerge (avg -45% net income swing), with margins mixed (Applied +80bps to 49.9%, ImmuCell +340bps to 45%). Institutional 13F snapshots reveal concentrated tech bets (Broadcom $250M Paradigm, Analog Devices $216M Timucuan, TSMC/Amazon ~$20M H Squared), signaling conviction in semis/AI/cloud. Forward-looking catalysts cluster in Q3 2026 (Applied rev ~$8.95B, Iridium deal close), while capital allocation leans shareholder-friendly (Applied div +15% to $0.53). Biotech-adjacent tech like INmune Bio's FDA Fast Track adds upside, but BDC/niche declines (Muzinich income -38% YoY) flag sector divergence. Overall, actionable alpha in growth outperformers pre-earnings/M&A closes, with risks in cash-strapped turnarounds.

13 high priority 28 medium 41 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 14, 2026

The 48 filings from NASDAQ-100 constituents and related entities reveal mixed Q1 2026 results across 15 earnings reporters, with 8/15 showing YoY revenue growth averaging +28% (e.g., ImmuCell +28%, INBS +46%, Intuitive Machines +200%), but persistent net losses in 12/15 amid rising G&A/exploration costs; margin expansions noted in 4/15 (e.g., INBS +370 bps gross margin). Key themes include accretive M&A (Iridium-Aireon adding $100M rev, Intuitive Machines-Lanteris boosting backlog to $1.1B), regulatory wins (TMC NOAA compliance by Q1 2027, INmune Bio FDA Fast Track), and institutional positioning via 13Fs favoring mining/tech (e.g., Mudita heavy in gold/mining, Paradigm in semis). Capital allocation leans conservative with dividend hikes (Applied Materials +15% to $0.53/share) but no buybacks noted; cash burns improved in 6/15 ops cash flow metrics. Portfolio-level trends show metals/biotech outperformance in milestones vs. services revenue softness (Intellinetics -8%). Forward catalysts cluster in H2 2026 (deal closes, trial data), signaling alpha in space/mining amid AI/semicon strength. Overall, bullish on strategic progress offsetting losses, with watch for cash runway in microcaps.

19 high priority 29 medium 48 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 14, 2026

Across 50 filings from the USA S&P 500 Financials stream (including banks, insurers, asset managers, and related SPACs/BDCs), dominant themes include SPAC quarterly resilience via trust interest income (10 SPACs averaging +$1.4M net income Q1 2026 despite ops losses and cash burns QoQ 20-67%), active debt markets with refinancings/upsizes (Lumen $2.4B Term B-5, Encore €325M notes), and mixed operating results in financial-adjacent firms (revenue growth in 8/15 ops cos avg +45% YoY skewed by small caps like Lifeway +37%, Karman +51%, but declines in larger like New Fortress -52%, Apartment REIT -4.8%). Period-over-period trends reveal margin expansions in outliers (Lifeway +360bps, Intelligent Bio +380bps to 50.5%) contrasting compressions elsewhere (SpringBig gross -16.8%), with capital allocation favoring debt raises over buybacks/dividends (News Corp $1B program ongoing, Muzinich no distributions). Forward-looking signals positive for growth (Lifeway FY2027 EBITDA $45-50M, Health In Tech scaling in $1T market), but SPAC risks high (Cantor 22M shares redeemed -$234M trust, Vernal going concern). Portfolio-level: Neutral 13Fs (Lord Abbett $30M, Gemsstock $949M energy tilt), bullish catalysts in M&A (Presidio $83M oil/gas), bearish cash burns signal caution; actionable now: Favor debt-access firms, monitor SPAC combos.

32 high priority 18 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 14, 2026

Across 50 filings primarily from small-cap biotechs, medtech, financials, and institutional 13F-HR snapshots (despite Consumer Staples stream focus, data skews pharma/services), Q1 2026 results show mixed performance: 8/15 quarterly reporters achieved revenue growth averaging +28% YoY (e.g., Intelligent Bio +46%, NIQ +11.1%), but 12/15 widened net losses (avg +45% YoY) amid rising opex/R&D, with cash burn improving in 6 cases. Key themes include M&A completion (Apellis acquired by Biogen at $41/share + CVR), positive clinical data (Cellectar 61.8% MRR), financing successes ($140M for Cellectar, $50M loan for Pelthos), and neutral 13F holdings in tech/ETFs signaling steady institutional conviction. Capital allocation leans defensive (dividends at Chicago BDC $0.34/share, reverse splits at Reliance), with forward guidance reaffirmed (NIQ 5-5.3% OCC growth). Portfolio-level trends: margin expansion in 4/10 (Intelligent Bio +380bps), but compression elsewhere; biotech outliers shine on milestones vs deteriorating liquidity in 7 firms (cash down >50% QoQ). Implications: tactical opportunities in catalysts (ASCO June 1), but watch liquidity risks and delistings amid volatile small-caps.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 14, 2026

Across the 50 filings in the USA S&P 500 Industrials stream, sentiment skews mixed-positive, driven by robust revenue growth in select industrials and energy-adjacent names like Forgent Power Solutions (+103% YoY to $379M revenue, +308% bookings) and LanzaTech (+26% YoY revenue), contrasting with persistent net losses in biotechs despite R&D progress. Period-over-period trends reveal 8/18 quarterly reporters with YoY revenue growth averaging 52% (outliers: Forgent 103%, Intelligent Bio 46%), but 10/18 showed net loss widening (avg +35% YoY) due to OpEx ramps; margins expanded in 5 cases (e.g., Forgent Adj EBITDA +96% to 22.4%). Institutional 13Fs (17 filings) highlight concentrated ETF exposure and defense industrials like Lockheed Martin ($10.5M in Campion), signaling broad sector conviction. Capital allocation shines with CSX's $5B buyback authorization atop $989M remaining, while M&A (Apellis acquired at $41/share + CVR) and debt raises (Constellation $2.2B notes) bolster liquidity. Forward-looking data flags raised guidances (Forgent FY26 rev +82% YoY midpoint, Hyperion +20%) and catalysts like Cabaletta's mid-2026 data readouts. Portfolio implications: Tactical buys in high-growth industrials amid biotech volatility, monitor June 2026 debt events.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 14, 2026

The S&P 500 Energy sector filings reveal strong shareholder confidence in governance at majors ConocoPhillips and Phillips 66, with near-unanimous approvals for directors, auditors, and exec comp amid rejected independent chair proposal at COP. A wave of 13F-HR disclosures from institutions like Blue Whale Capital ($2.1B portfolio, NVIDIA/Lam top), Fuller & Thaler ($29.7B, industrials focus), and Noked Israel ($677M, semis heavy) shows minimal evident energy exposure in top holdings, suggesting investor sidelining of oil/gas amid tech preference. Apartment Income REIT's Q1 10-Q flags mixed results: revenues -4.8% YoY to $193.7M, net loss $(28.9M) vs prior profit, but operating cash +376% YoY to $39.6M and interest expense -13.5% to $81.2M. No insider trades, M&A, or guidance changes noted across filings; capital allocation subdued with REIT capex -48% YoY to $12.8M. Portfolio-level trend: neutral institutional positioning, positive energy AGM outcomes contrast REIT weakness, implying stable but uninspiring sector momentum into Q2 2026.

2 high priority 10 medium 12 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 14, 2026

Across 50 SEC filings from May 14, 2026, primarily Q1 2026 10-Qs and 8-Ks, a key theme is robust revenue growth in 12/20 reporting companies averaging 67% YoY (e.g., RenovoRx +186%, Barfresh +92%, Aveanna +15.9%), driven by commercial expansion and segment gains, though offset by widening losses in 8 cases due to rising SG&A/R&D (avg +25% YoY). Biotech and healthcare firms dominate with clinical catalysts (e.g., Corvus Phase 1 success, RenovoRx trial enrollment by June), while telecom (Verizon) and consumer (YETI) show stable financing/debt access. Margin trends mixed: expansions in Enovix (+495% gross profit), compressions in YETI (-210 bps) and Versant (-11% op income). Capital allocation favors repurchases/dividends (Versant $100M buyback, YETI $500M auth increase) amid cash raises ($30M LanzaTech, $150M Cabaletta). Forward guidance raised in 4 firms (Aveanna rev +$40M, YETI sales 7-8%), signaling confidence; DJ30 exposure limited but Verizon's $4B notes positive. Portfolio implication: selective buys in growth biotechs/healthcare with near-term catalysts, caution on expense-heavy small caps; alpha from M&A/turnarounds like Kennedy-Wilson merger.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 14, 2026

Across 50 filings from May 14, 2026, primarily Q1 2026 results and 13F-HR holdings, the S&P 500 Consumer Discretionary stream reveals mixed performance with standout revenue accelerations in niche consumer-adjacent plays like Lifeway Foods (+37% YoY sales) and Newton Golf (operational expansions) amid broader sector challenges; however, energy-tied names like New Fortress Energy saw -52% YoY revenue collapses. Period-over-period trends highlight revenue growth in 7/15 operational filings averaging +85% YoY (outliers Forgent Power +103%, Scientist Home +321%), but margin pressures and capex surges led to net losses in 9/15 cases, with cash burns widening (e.g., WhiteFiber -33.8% QoQ cash). Institutional 13F-HRs (20+ filings) show heavy tech/consumer exposure (e.g., Nan Shan Life's $172M Alphabet, Swiss Life's massive Apple/Amazon), signaling conviction in discretionary leaders despite no direct insider buys noted. Forward-looking catalysts include raised guidances (Forgent FY2026 rev $1.35-1.39B, Hyperion DeFi gross profit $5-7M) and events like FREIT's Fall 2026 liquidation vote. Capital allocation leans toward capex/reinvestment (Lifeway $11M, Fermi $441M) over dividends/buybacks, with debt raises common (Wayfair $400M notes). Portfolio-level theme: Resilient growth pockets in food/golf/power contrast retail/energy weakness, favoring selective longs on guidance beats.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 14, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (despite cross-sector inclusions), Q1 2026 results from 10+ companies reveal robust revenue growth averaging +150% YoY in growth-oriented firms like Lifeway (+37%), Scientist Home (+321%), and UMeWorld (+85,000%), but persistent margin compression (-1,200bps avg in 5/8 cases) and opex explosions (+500% avg) drove wider net losses in 7/10, with cash burn accelerating and positions declining QoQ in 8/10 (e.g., Cellectar -37%, Senti -46%). Healthcare standouts include bullish biotech catalysts: Cellectar’s 61.8% major response rate in WM Phase 2b (iopofosine I 131), Editas’ 90% LDL-C reduction in NHP preclinical, and Senti Bio’s 70% YoY net loss reduction plus FDA pivotal trial nod. Institutional 13Fs (25/50 filings) signal conviction in healthcare via top holdings like McKesson (Seaview #1), AbbVie (multiple incl. Weaver, HRT, MFS), and biotechs Mineralys/Phathom (Catalys 93% portfolio). Capital allocation leans growth/reinvestment (Lifeway $11M capex, Cellectar $140M financing, Sixth Street $300M notes), with deal closes (HPE $987M) and backlogs (New Fortress $10B thru 2030) providing visibility. Portfolio implications: overweight biotech catalysts for alpha, underweight high-burn small caps amid liquidity risks; monitor ASCO June 1 and H1 2026 events.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 13, 2026

Across 32 filings in the USA S&P 500 Technology stream (broadly including software, AI, biotech tech, and related), sentiment is predominantly mixed (12/32 filings), with 6 negative and 4 positive, reflecting revenue growth in key tech names like Cisco (+12% YoY to $15.8B) and Formula Systems (+18% YoY to $2.6B) offset by declines in niche players like Planet 13 (-24.8% YoY) and CareView (-2% YoY). Period-over-period trends show 7/15 quarterly reporters with YoY revenue growth averaging +55% (outliers Dyadic +182%, MultiSensor AI +38%), but margins compressed in 5/10 (e.g., Cisco -200bps to 63.6%, MultiSensor -2% to 57%); net losses narrowed in 8/12 biotechs via cost cuts (Adicet R&D -23%, G&A -42%) and cash infusions (Immunic +$187M, Altimmune +$79M net). Forward-looking highlights include Cisco's raised FY2026 revenue guidance to $62.8-63.0B and AI infra to $4B, plus biotech catalysts like Adicet's prula-cel updates mid-2026. Capital allocation favors dividends (Cisco $0.42/share, Atmus $0.055/share), while 13F filings (7/32) reveal stable institutional tech exposure (e.g., Acadian's $3.89B Apple). Portfolio-level theme: Tech growth resilient amid biotech funding boom, but cash burns and margin pressures signal caution; actionable now: Buy Cisco on guidance raise, monitor biotechs for trial data.

11 high priority 21 medium 32 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 13, 2026

Across 32 filings from NASDAQ-100 related entities, Q1 2026 results reveal mixed performance with standout revenue growth in tech (Cisco +12% YoY to $15.8B) and biotechs/specialty firms (Dyadic +182% YoY, MultiSensor AI +38% YoY, Intelligent Bio +45% YoY), but persistent net losses and cash burn in 70% of operating companies despite narrowing in 6/12 cases (e.g., Adicet -28% YoY loss). Biotechs dominated with massive cash infusions (Immunic $200M, Altimmune $225M+, Tharimmune $87M), extending runways into 2027-2028, while REITs like Acadia showed robust NOI +19% YoY. Cisco raised FY2026 revenue guidance to $62.8-63.0B (+AI infra to $4B) and declared $0.42 dividend, signaling conviction; SPACs and miners exhibited typical pre-deal losses amid asset builds. Portfolio trends include margin compression (Cisco -200bps gross, MultiSensor -2%) averaging -100bps across 5 reporters, offset by capex discipline and forward catalysts like 5+ clinical readouts H2 2026. Institutional 13Fs (Group One, State Farm, Acadian) show stable mega-cap tech/energy holdings, neutral positioning. Implications: Tactical buys in growth biotechs/tech with catalysts, caution on high-burn explorers/miners.

15 high priority 17 medium 32 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 13, 2026

Across 50 filings in the USA S&P 500 Financials stream (primarily Q1 2026 10-Qs and 13F-HRs filed May 13, 2026), asset managers dominate with 13F disclosures showing heavy allocations to tech giants (Apple, Amazon, Nvidia, Alphabet topping most portfolios) and broad ETFs, signaling low conviction in pure financials amid diversified strategies. Financial institutions exhibit mixed period-over-period trends: net interest income (NII) growth in banks like Bogota Financial (+23.2% YoY) contrasts with deposit declines (-7.9% QoQ) and modest net income drops (-3.4% YoY), while insurers like UTG Inc surged net income +81% YoY on investment gains and Lincoln National revenues +17.9% YoY despite net losses. Capital allocation leans shareholder-friendly with NB Bancorp completing 5% buyback (cumulative 16% since 2025) and funds like NMF SLF I declaring distributions amid NAV declines. Non-core filings (e.g., oil, pharma) show volatile revenues/losses, but financials highlight resilience in investment income (+14-39% YoY in funds) offset by unrealized depreciation. Portfolio-level: 30+ 13Fs aggregate ~$200B+ in tech/ETF holdings vs sparse financial-specific bets, implying relative underweight in banks/insurers. Key implication: Watch deposit trends and Q2 catalysts for NIM pressure, with buybacks signaling undervaluation.

18 high priority 32 medium 50 total filings